ADXS11-001 immunotherapy targeting HPV-E7: Updated survival and safety data from a Phase 2 study in Indian women with recurrent cervical cancer Robert Petit 1 and Partha Basu 2 1 Advaxis, Inc. Princeton, NJ 2 Chittaranjan National Cancer Institute, Kolkata, India Abstract Life Cycle of Lm in APC Lm-LLO Immunotherapy Safety: Frequency of SAEs in 110 patient Phase 2: ADXS11-001 vs. Chemotherapy Overall Survival Lm-LLO-E7-15 Best Response Data Conclusions Case Study: Patient 110-002 Landmark Survival Duration of Response (PFS) Overall Survival: Aggressive vs. Non- Aggressive Disease Response by Aggressiveness of Disease & Treatment Group Lm-LLO-E7-015: A Randomized Phase 2 Study to Assess the Safety & Efficacy of ADXS-HPV +/- cisplatin Treatment for Recurrent Cervical Cancer Trial Design: Lm-LLO-E7-15 Safety